Bristol-Myers Squibb Co Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy (ipilimumab), in Patients with Advanced Melanoma
Bristol-Myers Squibb Co announced results from Study 004, a dose-ranging Phase 1 trial (n=86) evaluating the safety and anti-tumor activity of its investigational PD-1 receptor blocker, nivolumab, combined either concurrently (n=53) or sequentially (n=33) with Yervoy (ipilimumab) in patients with advanced melanoma. In patients who received the dose used in the Phase 3 trial (1 mg/kg nivolumab + 3 mg/kg Yervoy)in the concurrent regimen, 53% (n= 9 of 17) had confirmed objective responses (OR) by mWHO criteria. In all nine of these responders, tumors shrank by at least 80% by the time of the first scheduled clinical treatment assessment (12 weeks), including three complete responses (CRs). In response-evaluable patients across all concurrent cohorts, 40% (n= 21 of 52) had an OR. Sixteen patients (31%) had tumor shrinkage of at least 80% by the time of the first clinical trial assessment, including five CRs. Responses were ongoing among 19 of 21 responders, with responses lasting from between 6.1+ to 72.1+ weeks at the time of data analysis. Clinical activity was observed in both the concurrent and sequenced regimens. Median overall survival has not been reached after approximately 13 months of median follow up in the concurrent cohorts. The estimated one-year survival rate across all concurrent cohorts was 82% (95% CI 69.0 - 94.4%).
Latest Developments for Bristol-Myers Squibb Co
- FDA advisory committee recommends AstraZeneca PLC And Bristol-Myers Squibb Co investigational SGLT2 inhibitor dapagliflozin
- FDA advisory committee votes on AstraZeneca PLC and Bristol-Myers Squibb Co investigational medicine metreleptin
- Bristol-Myers Squibb Co announces four-year data from Phase 3 DASISION trial comparing Sprycel (dasatinib) to Imatinib in first-line treatment of adults with Ph+ CP-CML
- Bristol-Myers Squibb Co Submits All-Oral, Interferon-Free And Ribavirin-Free Treatment Regimen For Regulatory Review In Japan For Patients With Chronic Hepatitis C Infection
Latest Key Developments in Pharmaceuticals
- Plethora Solutions Holdings PLC announces CEO Appointment
- Merck & Co Inc announces launch of new business focused on weight management interventions in U.S.
- Coronado Biosciences Inc announces management changes
- Auxilium Pharmaceuticals Inc submits application to the FDA requesting approval of xiaflex for concurrent treatment of multiple palpable cords
- Share this
- Digg this